Core Viewpoint - 康沣生物-B (06922) reported a significant increase in revenue and a reduction in losses for the first half of 2025, driven by the sales of newly approved respiratory intervention products [1] Financial Performance - Revenue reached 51.106 million yuan, representing a year-on-year increase of approximately 162% [1] - Gross profit amounted to 34.312 million yuan, reflecting a year-on-year growth of about 125% [1] - Loss attributable to the parent company narrowed to 23.817 million yuan, a reduction of 54.35% compared to the previous year [1] - Earnings per share reported a loss of 0.1 yuan [1] Product and Market Development - Revenue growth was primarily driven by the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products distributed by 波科国际医疗贸易 (Shanghai) Co., Ltd. also increased during the reporting period [1] Strategic Initiatives - The reduction in losses is attributed to the company's optimized development strategy and effective measures implemented for group cost control [1]

Core Viewpoint - 康沣生物-B (06922.HK) reported significant revenue growth and reduced losses for the six months ending June 30, 2025, driven by increased sales of respiratory intervention products following regulatory approval [1] Financial Performance - Revenue increased to RMB 51.1 million, representing a year-on-year growth of 162.4% [1] - Losses decreased from RMB 56.0 million for the six months ending June 30, 2024, to RMB 27.2 million for the same period in 2025, a reduction of RMB 28.8 million or 51.4% [1] Product Development - The revenue growth was primarily attributed to the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products distributed by 波科国际医疗贸易 (Shanghai) Co., Ltd. also contributed to the revenue increase during the reporting period [1]